Yan Mei Goh1, Zaher Toumi2, Ravindra S Date3,4. 1. Department of Upper Gastrointestinal Surgery, Lancashire Teaching Hospital NHS Foundation Trust, Chorley, PR7 1PP, UK. 2. Department of Bariatric Surgery, McGill University, 845 Rue Sherbrooke O, Montreal, QC, H3A 0G4, Canada. 3. Department of Upper Gastrointestinal Surgery, Lancashire Teaching Hospital NHS Foundation Trust, Chorley, PR7 1PP, UK. ravidate@hotmail.com. 4. Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK. ravidate@hotmail.com.
Abstract
BACKGROUND: Bariatric surgery results in remission of type 2 diabetes mellitus in a significant proportion of patients. Animal research has proposed the foregut and hindgut hypotheses as possible mechanisms of remission of T2DM independent of weight loss. These hypotheses have formed the basis of investigational procedures designed to treat T2DM in non-obese (in addition to obese) patients. The aim of this study was to review the procedures that utilise the foregut and hindgut hypotheses to treat T2DM in humans. METHODS: A systematic review was conducted to identify the investigational procedures performed in humans that are based on the foregut and hindgut hypotheses and then to assess their outcomes. RESULTS: Twenty-four studies reported novel procedures to treat T2DM in humans; only ten utilised glycated haemoglobin A1c (HbA1c) in their definition of remission. Reported remission rates were 20-40 % for duodenal-jejunal bypass (DJB), 73-93 % for duodenal-jejunal bypass with sleeve gastrectomy (DJB-SG), 62.5-100 % for duodenal-jejunal bypass sleeve (DJBS) and 47-95.7 % for ileal interposition with sleeve gastrectomy (II-SG). When using a predetermined level of HbA1c to define remission, the remission rates were lower (27, 63, 0 and 65 %) for DJB, DJB-SG, DJBS and II-SG. CONCLUSIONS: The outcomes of the foregut- and hindgut-based procedures are not better than the outcomes of just one of their components, namely sleeve gastrectomy. The complexity of these procedures in addition to their comparable outcomes to a simpler operation questions their utility.
BACKGROUND: Bariatric surgery results in remission of type 2 diabetes mellitus in a significant proportion of patients. Animal research has proposed the foregut and hindgut hypotheses as possible mechanisms of remission of T2DM independent of weight loss. These hypotheses have formed the basis of investigational procedures designed to treat T2DM in non-obese (in addition to obese) patients. The aim of this study was to review the procedures that utilise the foregut and hindgut hypotheses to treat T2DM in humans. METHODS: A systematic review was conducted to identify the investigational procedures performed in humans that are based on the foregut and hindgut hypotheses and then to assess their outcomes. RESULTS: Twenty-four studies reported novel procedures to treat T2DM in humans; only ten utilised glycated haemoglobin A1c (HbA1c) in their definition of remission. Reported remission rates were 20-40 % for duodenal-jejunal bypass (DJB), 73-93 % for duodenal-jejunal bypass with sleeve gastrectomy (DJB-SG), 62.5-100 % for duodenal-jejunal bypass sleeve (DJBS) and 47-95.7 % for ileal interposition with sleeve gastrectomy (II-SG). When using a predetermined level of HbA1c to define remission, the remission rates were lower (27, 63, 0 and 65 %) for DJB, DJB-SG, DJBS and II-SG. CONCLUSIONS: The outcomes of the foregut- and hindgut-based procedures are not better than the outcomes of just one of their components, namely sleeve gastrectomy. The complexity of these procedures in addition to their comparable outcomes to a simpler operation questions their utility.
Entities:
Keywords:
Foregut theory; Hindgut theory; Remission ot type 2 diabetes
Authors: Bruno Geloneze; Sylka Rodovalho Geloneze; Elinton Chaim; Fernanda Filgueira Hirsch; Ana Claudia Felici; Giselle Lambert; Marcos Antonio Tambascia; José Carlos Pareja Journal: Ann Surg Date: 2012-07 Impact factor: 12.969
Authors: Eduardo G H de Moura; Bruno C Martins; Guilherme S Lopes; Ivan R Orso; Suzana L de Oliveira; Manoel P Galvão Neto; Marco A Santo; Paulo Sakai; Almino C Ramos; Arthur B Garrido Júnior; Marcio C Mancini; Alfredo Halpern; Ivan Cecconello Journal: Diabetes Technol Ther Date: 2011-09-20 Impact factor: 6.118
Authors: Bryan J Sandler; Roberto Rumbaut; C Paul Swain; Gustavo Torres; Luis Morales; Lizcelly Gonzales; Sarah Schultz; Mark Talamini; Santiago Horgan Journal: Surg Endosc Date: 2011-04-13 Impact factor: 4.584
Authors: Efstathios V Kotidis; George G Koliakos; Vasilios G Baltzopoulos; Konstantinos N Ioannidis; John G Yovos; Spiros T Papavramidis Journal: Obes Surg Date: 2006-11 Impact factor: 4.129
Authors: Almino C Ramos; Manoel P Galvão Neto; Yglésio Moyses de Souza; Manoela Galvão; Abel H Murakami; Andrey C Silva; Edwin G Canseco; Raúl Santamaría; Trino A Zambrano Journal: Obes Surg Date: 2008-11-06 Impact factor: 4.129
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Lina Shibib; Mo Al-Qaisi; Ahmed Ahmed; Alexander D Miras; David Nott; Marc Pelling; Stephen E Greenwald; Nicola Guess Journal: Vasc Health Risk Manag Date: 2022-06-14